Contrasting Atara Biotherapeutics (NASDAQ:ATRA) and Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.

Profitability

This table compares Taysha Gene Therapies and Atara Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Taysha Gene Therapies N/A -51.87% -40.29%
Atara Biotherapeutics -368.58% N/A -73.19%

Insider & Institutional Ownership

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Taysha Gene Therapies and Atara Biotherapeutics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Taysha Gene Therapies $5.49 million 243.56 -$109.00 million ($0.43) -9.53
Atara Biotherapeutics $120.77 million 0.65 $32.69 million ($1.01) -7.62

Atara Biotherapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Taysha Gene Therapies has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Taysha Gene Therapies and Atara Biotherapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Taysha Gene Therapies 1 0 11 2 3.00
Atara Biotherapeutics 1 1 1 1 2.50

Taysha Gene Therapies presently has a consensus target price of $12.75, suggesting a potential upside of 210.98%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential upside of 23.38%. Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Taysha Gene Therapies is more favorable than Atara Biotherapeutics.

Summary

Taysha Gene Therapies beats Atara Biotherapeutics on 10 of the 15 factors compared between the two stocks.

About Taysha Gene Therapies

(Get Free Report)

Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company’s lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha’s research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy.

About Atara Biotherapeutics

(Get Free Report)

Atara Biotherapeutics is a biotechnology company focused on developing allogeneic T-cell immunotherapies for cancer and other serious diseases. Founded in 2012 and based in Thousand Oaks, California, the company’s approach uses immune cells from donors rather than cells collected from each individual patient. Its lead therapy, tabelecleucel, is an Epstein-Barr virus (EBV)-specific T-cell treatment for EBV-positive post-transplant lymphoproliferative disease, a rare complication that can occur after an organ or stem-cell transplant.

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.